Alopecia Areata: A Global Approach for Dermatology NPs
Alopecia, in its various forms, is a complex condition with deep-rooted genetic, hormonal, and psychosocial implications that extend far beyond a cosmetic concern. As Nurse Practitioners (NPs), we are often the first point of contact for patients struggling with hair loss, making our comprehensive understanding and holistic approach essential for effective care and building patient trust. However, traditional assessment methods often fall short, focusing primarily on visible hair loss while neglecting the profound emotional distress, quality of life impairment, and associated comorbidities that patients experience. This article will deconstruct the latest research on alopecia, from its genetic underpinnings to emerging treatments and the critical need for a patient-centered approach that considers the whole person. Members of the Alliance of Cosmetic Nurse Practitioners and participants in our Alopecia Residency will receive actionable insights, innovative DNP and PhD research ideas, and strategic business opportunities to elevate their practice and champion overdue care for all patients struggling with hair loss.
Background and Significance
Alopecia, encompassing conditions like androgenetic alopecia (AGA) and alopecia areata (AA), affects millions of individuals globally. AGA, commonly known as male- and female-pattern baldness, is a hereditary form of gradual hair loss driven by hair follicle sensitivity to androgens, with genetic risk factors near the androgen receptor (AR) gene influencing susceptibility.
In men, it usually presents as a receding hairline and thinning at the crown.
In women, it typically shows up as diffuse thinning over the crown and widening of the part, while the hairline is usually preserved.
Beyond its cosmetic impact, baldness has been associated with broader endocrine, metabolic, and cardiovascular diseases, highlighting the systemic effects of sex hormones. Moreover, elevated stress, mediated by increased cortisol, can exacerbate hair loss by impacting hair follicle cycles.
Alopecia areata (AA), a chronic autoimmune disease characterized by non-scarring hair loss, is a particularly significant concern, profoundly diminishing quality of life (QoL) and strongly linked to anxiety, depression, lowered self-esteem, and social isolation (Stevanovic et al., 2025; Benigno et al., 2020; Ahmed et al., 2023). Globally, over 30% of individuals with AA report depression and anxiety, a rate significantly higher than in healthy controls. Experts have even suggested that quality of life impairment alone can be a sufficient criterion for systemic therapy, and a history of anxiety, depression, or suicidal ideation due to AA can warrant treatment initiation.
The clinical course of AA is often unpredictable, with periods of relapse and remission, and it imposes a substantial socioeconomic and psychological burden on patients and healthcare systems worldwide (Stevanovic et al., 2025; Ding et al., 2025; Zhou et al., 2025). Globally, the management of this condition is characterized by notable challenges alongside significant advancements in both diagnosis and treatment (Ahmed et al., 2023). This comprehensive overview integrates findings from recent studies to highlight the multifaceted nature of AA, emphasizing its socioeconomic impact, diagnostic intricacies, therapeutic evolutions, and geographical disparities.
Challenges in Alopecia Areata Management
Several systemic and regional challenges impede the effective diagnosis and treatment of AA globally:
Data Gaps and Underestimation of Burden: Comprehensive global data on the socioeconomic impact of AA are notably lacking from most countries in Africa, Scandinavia, Eastern Europe, the Middle East, South Asia, and parts of Latin America (Stevanovic et al., 2025). Specifically, 48% of Global Burden of Disease (GBD) regions, particularly middle- and low-income countries, have insufficient data on the prevalence or incidence of AA (Jeon et al., 2024). This leads to a potential underestimation of the true global burden, especially in low Socio-Demographic Index (SDI) regions, where poor health awareness and less-severe cases may not be diagnosed or treated (Wang et al., 2022). Data quality is further compromised by fragmented hospital records, for example, in sub-Saharan Africa, which can systematically underestimate mild cases and true prevalence rates (Ding et al., 2025). Studies from these regions often suffer from short follow-up periods, are monocentric, and have small sample sizes, further affecting data robustness (Ahmed et al., 2023).
Lack of Registries and Standardized Protocols: There is a lack of formal registries in Africa and the Middle East, limiting clinical information on prevalence, incidence, and treatment (Ahmed et al., 2023). This absence of region-specific guidelines results in non-uniform treatment plans among dermatologists (Ahmed et al., 2023). Globally, there is a recognized need for standardized, comparable data to develop consistent treatment protocols and integrated care pathways (Stevanovic et al., 2025).
Diagnostic Limitations: While tools like the Alopecia Assessment Tool (ALTO), Severity of Alopecia Tool (SALT), and Alopecia Areata Scale exist, their accuracy for patient self-assessment or use with remote photography has not been fully validated across diverse populations, making accurate disease severity classification challenging (Benigno et al., 2020). It can also be difficult to distinguish mild AA or diffuse AA from other types of hair loss, like androgenic alopecia, particularly with photographic evidence alone (Benigno et al., 2020). Diagnostic inconsistencies are exacerbated by a lack of standardized tools and low dermatologist-to-population ratios, especially in low-SDI regions (Ding et al., 2025).
Limited Treatment Efficacy and Accessibility: Many existing treatment options for AA are limited in effectiveness and often used off-label, without robust clinical trial validation, and treatment options for pediatric and adolescent populations are insufficient (Ahmed et al., 2023; Benigno et al., 2020). Resource-limited settings face challenges in accessing appropriate diagnostic tools, compassionate use programs, and therapeutic resources due to heterogeneity across healthcare facilities (Ahmed et al., 2023). Public healthcare systems in many Middle Eastern and African countries are underfunded and understaffed, leading to limited access to basic healthcare services, and even private systems are often unaffordable for a significant portion of the population (Ahmed et al., 2023). The absence of critical parameters in global public health databases, such as national healthcare resource allocation, insurance coverage, and clinical adoption rates of innovative therapies, also hinders the comprehensive understanding of regional disparities in therapeutic accessibility (Ding et al., 2025).
Financial and Psychosocial Burden: AA imposes a substantial financial burden on patients due to high out-of-pocket expenses for alternative therapies such as wigs, hairpieces, and cosmetic camouflage (Stevanovic et al., 2025; Ahmed et al., 2023). Many patients report being unable to afford treatments (Ahmed et al., 2023). Insurance approval is a major obstacle, as AA is frequently classified as a cosmetic condition rather than a serious health issue, leading to treatment interruptions or discontinuation and subsequent relapses (Ahmed et al., 2023). The social stigma associated with visible hair loss also discourages patients, particularly women, from seeking treatment, contributing to underreporting (Ahmed et al., 2023; Zhou et al., 2025). Over 30% of AA sufferers report depression and anxiety across the globe, which is significantly higher than in healthy controls, making psychological impact an important criterion for assessing AA severity (Ahmed et al., 2023; Stevanovic et al., 2025). Children and adults with AA frequently experience depressive and anxiety symptoms, with 7% to 17% requiring psychiatric intervention (Adhanom et al., 2025).
Advancements in Alopecia Areata Management
Despite these challenges, significant progress has been made, particularly in understanding disease epidemiology and developing targeted therapies:
Improved Epidemiological Understanding: Recent studies, particularly those utilizing GBD 2019 and GBD 2021 databases, have provided more comprehensive global, regional, and national epidemiological data on AA (Wang et al., 2022; Ding et al., 2025; Li et al., 2025; Jeon et al., 2024). This includes insights into age, sex, and socioeconomic disparities in incidence and prevalence. For example, studies highlight that while age-standardized incidence rates (ASIR) in high-income countries are high but declining, they are rapidly rising in developing countries, possibly due to improved disease recognition and reporting (Ding et al., 2025; Wang et al., 2022). In the US, the clinician-adjudicated point prevalence of AA was 0.21%, and the self-reported lifetime prevalence was 2.51% (Benigno et al., 2020). Globally, the incidence in females is consistently higher than in males, almost twice as high, with young and female individuals (aged 25–39 years or 30-34 years) bearing a disproportionately high burden (Ding et al., 2025; Wang et al., 2022; Li et al., 2025).
Racial and Hair Color Insights: Research now indicates higher rates of AA in Hispanic/Latino, Black, and Asian children and women compared to White individuals in the US (Adhanom et al., 2025; Thompson et al., 2018). New findings suggest that darker natural hair colors may be associated with a higher risk of AA, while lighter hair colors (red or blonde) may be associated with a lower risk (Kamal et al., 2024). These differences in hair color could contribute to previously noted racial variations in AA incidence, potentially influencing dermatologists’ perspectives on disease epidemiology (Kamal et al., 2024).
Emergence of Janus Kinase (JAK) Inhibitors: This represents a major breakthrough in AA treatment (Ding et al., 2025; Li et al., 2025).
o Baricitinib (a JAK1/JAK2 inhibitor) is the first and currently only FDA-approved systemic treatment for severe AA in adults, demonstrating high efficacy and a favorable safety profile in phase 3 clinical trials (BRAVE-AA1 and BRAVE-AA2) (Moussa et al., 2024; Ding et al., 2025).
o Ritlecitinib (a JAK3/TEC kinase inhibitor) has also shown promising results in phase 2b-3 trials (Li et al., 2025; Ding et al., 2025).
These advancements are particularly impactful in high-SDI countries, potentially mitigating the disease burden (Ding et al., 2025). Recent research hotspots revolve around clinical trials and evaluating these modalities, along with autologous derivative products (Ding et al., 2025). Autologous derivative products are treatments created from a patient’s own biological materials and then reapplied for therapeutic or cosmetic purposes. Because these products originate from the individual, they are inherently biocompatible and carry a lower risk of rejection or adverse reaction compared to donor- or synthetic-based options. Common examples include platelet-rich plasma (PRP), which is processed from a patient’s blood to stimulate collagen production and hair growth, and autologous fibroblast injections, where a person’s own skin cells are harvested, cultured, and reinjected to improve texture and scarring. These therapies fall under the growing field of regenerative medicine, leveraging the body’s natural capacity for repair and renewal.
Multidimensional Severity Assessment: The development of the Alopecia Areata Severity and Morbidity Index (ASAMI) is a significant advancement in diagnosis and treatment planning (Moussa et al., 2024). This tool aims to capture the overall disease impact beyond just scalp hair loss, incorporating factors like disease duration, number of relapses, treatment response, visibility of hair loss, and involvement of facial hair (eyebrows, eyelashes, beard) and nails, as well as psychosocial impact (anxiety, depression, quality of life) (Moussa et al., 2024). The Alopecia Areata Investigator Global Assessment (AA-IGA) scale has also been accepted for classifying scalp AA severity (Moussa et al., 2024).
Guidance for Funding and Treatment Initiation: The ASAMI consensus study has provided expert-agreed criteria that can guide third-party payers to fund JAK inhibitors for patients with specific characteristics, irrespective of SALT score (Moussa et al., 2024). These include episodes lasting 12 months or more, difficulty with cosmetic camouflage, beard involvement with cultural/religious significance, nail involvement causing functional or occupational impairment, and a history of anxiety, depression, or suicidal ideation due to or exacerbateImage source: The Full Spectrum of Dermatology: A Diverse and Inclusive Atlasd by AA (Moussa et al., 2024). These insights are crucial for identifying appropriate candidates for emerging systemic treatments, especially in resource-limited settings.
Other Emerging Therapies: Beyond JAK inhibitors, other modalities like microneedling, laser therapy, and stem cell therapy are also being explored (Ahmed et al., 2023). These advancements represent a move towards more comprehensive, patient-centered approaches to AA management, acknowledging both the physical and profound psychological impacts of the disease, and are crucial for optimizing diagnostic and therapeutic strategies globally (Ding et al., 2025).
Image source: The Full Spectrum of Dermatology: A Diverse and Inclusive Atlas
Implications for Dermatology and Cosmetic Nurse Practitioners
We play a critical and multifaceted role in managing alopecia, particularly conditions like androgenetic alopecia (AGA) and alopecia areata (AA). As nurses we are often the first point of contact for patients, whether you're a nurse at the bedside or practicing in primary care, our comprehensive and holistic approach is essential for effective care and building patient trust.
Connecting Science to Clinical Practice: The genetic and hormonal basis of AGA means that we should conduct a detailed family history of baldness, as genetic risk factors near the androgen receptor (AR) gene influence susceptibility. We must also recognize that hair loss is not just a cosmetic issue; it is associated with broader endocrine, metabolic, and cardiovascular diseases, and elevated stress can exacerbate hair loss by impacting hair follicle cycles.
Comprehensive Assessment: Beyond visual inspection, you should conduct a thorough intake, inquiring about family history, lifestyle, and overall health to identify potential underlying comorbidities and personal and familial history of autoimmune disorders, such as atopic disease, vitiligo, and thyroid conditions, which are commonly associated with alopecia.
Psychosocial Screening: Alopecia profoundly diminishes quality of life and is strongly linked to anxiety, depression, lowered self-esteem, and social isolation. You must proactively screen for these psychological impacts, validate patients' feelings, and integrate mental health support into care plans.
Patient Education and Treatment Pathways: You should be knowledgeable about evolving treatments like Janus kinase (JAK) inhibitors for conditions such as alopecia areata, which target specific immune pathways. You are expected to educate patients about the efficacy and safety of these newer therapies, while also discussing the realities of cost and access, which vary significantly across regions.
Elevating Expertise and Trust: By integrating these scientific insights, from genetic and hormonal influences to psychosocial impacts and emerging treatments, into our clinical practice, we can build deeper patient trust. This approach moves beyond simply treating symptoms, positioning NPs as knowledgeable and empathetic experts in a condition that significantly impacts patients' physical and emotional well-being.
Clinical Pearls / Key Teaching Points for Patient Education
Here are some concise, memorable teaching points you can share with patients:
"Your genes play a big role in common hair loss. Male- and female-pattern baldness, or androgenetic alopecia, is largely inherited and influenced by certain hormones called androgens. It's not just a sign of aging; your family history gives us important clues about your hair journey."
"Hair loss isn't just about appearance; it can be connected to your overall health. Conditions like male- and female-pattern baldness have been linked to other health issues, including problems with hormones, metabolism, and even heart health. That's why we look at your whole health picture."
"It's completely normal for hair loss to affect how you feel. Many people with hair loss, especially alopecia areata, experience anxiety, depression, or lower self-esteem. Your emotional well-being is important, and we're here to support you through all aspects of this condition."
"For alopecia areata, the color of your natural hair might influence your risk. Studies suggest that people with darker hair colors could have a higher risk of developing alopecia areata, while lighter hair colors might be associated with a lower risk. This helps us understand the disease better."
"Exciting new treatments are on the horizon, especially for autoimmune hair loss. Researchers are making significant progress with medications like Janus kinase (JAK) inhibitors, which target the immune system pathways causing conditions like alopecia areata, offering promising results for many."
"Comprehensive care is key. Because hair loss can be influenced by many factors, from your genes and hormones to your environment and stress levels, a thorough evaluation that considers your unique situation is the best way to develop an effective management plan which may include a dermatologists, nurse practitioner, physician associate, trichologist, speciality trained hair stylist, integrative specialist, pharmacist, and immunologist (immune specialists) to name a few."
"Although we often see alopecia areata on the scalp, it can also affect other areas like the beard, eyebrows, eyelashes, underarms, and sometimes even inside the nose or ears. Hair often starts to grow back as fine white hairs, which will gradually thicken and regain their natural color, this is a good sign that your hair is recovering. You might also notice short, “exclamation point” hairs, which are a classic sign of this condition, and sometimes changes in the nails, like brittleness, pitting, or ridges. In people with coarser hair, hair loss at the front of the scalp can look a lot like traction alopecia, which is why sharing your full hair history and having a careful exam, and sometimes a biopsy, helps us make sure we’re treating the right type of hair loss."
Invite patients to see what Alopecia Areata and Androgenetic Alopecia looks like on their skin by visiting See My Skin, the result of a collaboration with Vaseline and HUED.
Conclusion Nurse Practitioners stand at the forefront of evolving alopecia care, uniquely positioned to transform patient outcomes. By integrating knowledge of the genetic and physiological drivers of hair loss with an awareness of its psychosocial and economic impact, NPs deliver holistic, patient-centered care. We move beyond treating visible symptoms, addressing emotional well-being, quality of life, and the systemic access barriers patients face. Through embracing emerging therapies such as JAK inhibitors and championing equity in access and awareness, NPs empower patients to navigate the complexities of hair loss with confidence and trust.
This article reflects just a fraction of the conversations taking place within the Alliance of Cosmetic Nurse Practitioners™ Alopecia Residency, the first program of its kind in nursing. Over the course of this year-long journey, we are building clinical confidence, advancing research, and strengthening business innovation in the field of hair disorders. While we’re glad to share highlights here, full access, including live lectures, guided research support for graduate and doctoral projects, and weekly mentorship on implementation in clinical practice and business, is available exclusively to our members. Additionally, members can access the newest podcast audio that accompanies this article, inside the ACNP community. We invite you to continue this dialogue with us as we shape the future of dermatology and cosmetics together.
About the Author
Dr. Kimberly Madison, DNP, AGPCNP-BC, WCC, is a Board-Certified, Doctorally-prepared Nurse Practitioner, educator, and author dedicated to advancing dermatology nursing education and research with an emphasis on skin of color. As the founder of Mahogany Dermatology Nursing | Education | Research™ and the Alliance of Cosmetic Nurse Practitioners™, she expands access to dermatology research, business acumen, and innovation while also leading professional groups and mentoring clinicians. Through her engaging and informative social media content and peer-reviewed research, Dr. Madison empowers nurses and healthcare professionals to excel in dermatology and improve patient care.
Al Hammadi, A., Parmar, N. V., Aljefri, K., Al Sharif, O., Abdallah, M., Ahmed, H. M., & Ammoury, A. (2023). Review on alopecia areata in the Middle East and Africa: Landscape and unmet needs. Dermatology and Therapy (Heidelberg), 13, 1435–1464.
Benigno, M., Anastassopoulos, K. P., Mostaghimi, A., Udall, M., Daniel, S. R., Cappelleri, J. C., Chander, P., Wahl, P. M., Lapthorn, J., Kauffman, L., Chen, L., & Peeva, E. (2020). A large cross-sectional survey study of the prevalence of alopecia areata in the United States. Clinical, Cosmetic and Investigational Dermatology, 13, 259–266.
Ding, H., Yu, Z., Yao, H., Xu, X., Liu, Y., & Chen, M. (2025). Global burden of alopecia areata from 1990 to 2019 and emerging treatment trends analyzed through GBD 2019 and bibliometric data. Scientific Reports, 15, 20909.
Jeon, J. J., Jung, S.-W., Kim, Y. H., Parisi, R., Lee, J. Y., Kim, M. H., Lee, W.-S., & Lee, S. (2024). Global, regional and national epidemiology of alopecia areata: A systematic review and modelling study. British Journal of Dermatology, 191(3), 325–335.
Kamal, K., Xiang, D., Young, K., Fisher, D. E., Mostaghimi, A., & Theodosakis, N. (2024). Association between natural hair color, race, and alopecia. Dermatology and Therapy (Heidelberg), 14, 2109–2117.
Li, X., Liu, H., Ren, W., Zhu, Q., Yin, P., Wang, L., Zhang, J., Qi, J., & Zhou, C. (2025). Burden of alopecia areata in China, 1990–2021: Global Burden of Disease Study 2021. Chinese Medical Journal, 138(3), 318–324.
Moussa, A., Bennett, J. L., Wall, D., Meah, N., York, K., Bokhari, L., Asfour, T., Rees, H., Abraham, L. S., Asz-Sigall, M. A., Bergfeld, W. F., Betz, S., Bhoyrul, B., Blume-Peytavi, U., Callender, V. D., Combalia, M., Cotsarelis, G., Craiglow, B. G., Donovan, J. M. A., … Sinclair, R. (2024). The Alopecia Areata Severity and Morbidity Index (ASAMI) Study—Results From a Global Expert Consensus Exercise on Determinants of Alopecia Areata Severity. JAMA Dermatology, 160(3), 341–350.
Stevanovic, K., Pereira, M., Nguyen, O., van Hofman, I., Meesch, C., & Zuberbier, T. (2025). 20 years of the socioeconomic impact of atopic dermatitis and alopecia areata from around the globe. Clinical and Translational Allergy,
Janivara, R., Hazra, U., Pfennig, A., Harlemon, M., Kim, M. S., Eaaswarkhanth, M., Chen, W. C., Ogunbiyi, A., Kachambwa, P., Petersen, L. N., Jalloh, M., Mensah, J. E., Adjei, A. A., Adusei, B., Joffe, M., Gueye, S. M., Aisuodionoe-Shadrach, O. I., Fernandez, P. W., Rohan, T. E., Andrews, C., Rebbeck, T. R., Adebiyi, A. O., Agalliu, I., & Lachance, J. (2025). Uncovering the genetic architecture and evolutionary roots of androgenetic alopecia in African men. Human Genetics and Genomics Advances, 6(3), 100428.
Thompson, J. M., Park, M. K., Qureshi, A. A., & Cho, E. (2018). Race and alopecia areata amongst US women. Journal of Investigative Dermatology Symposium Proceedings, 19, S47–S50.
Vañó-Galván, S., Saceda-Corralo, D., Blume-Peytavi, U., Cucchía, J., Dlova, N. C., Dias, M. F. R. G., Grimalt, R., Guzmán-Sánchez, D., Harries, M., Ho, A., Holmes, S., Larrondo, J., Mosam, A., Oliveira-Soares, R., Pinto, G. M., Piraccini, B. M., & Pirmez, R. (2019). Frequency of the types of alopecia at twenty-two specialist hair clinics: A multicenter study. Skin Appendage Disorders, 5, 309–315.
Wang, H., Pan, L., & Wu, Y. (2022). Epidemiological trends in alopecia areata at the global, regional, and national levels. Frontiers in Immunology, 13, 874677.
.svg)
.svg)
.svg)
.png)
%20copy.png)
.jpg)
